Patents Examined by Niloofar Rahmani
  • Patent number: 11072609
    Abstract: The present invention relates to a method for preparing halogenated imidazopyridine derivatives of the formula (II) proceeding from compounds of the formula (I) via intermediates of the formula (IVa) or (IVb) in which the radicals Q, Z, R1, R3, R4, Rc, A1 and A2 have the definitions stated. The invention further relates to such halogenated imidazopyridine derivatives, and also intermediates and the reaction products of compounds of the formula (II) to give compounds of the formula (III) in which the specified structural elements have the definitions stated.
    Type: Grant
    Filed: February 5, 2018
    Date of Patent: July 27, 2021
    Assignees: Bayer Aktiengesellschaft, Bayer CropScience Aktiengesellschaft
    Inventors: Marc Mosrin, Ruediger Fischer, Dominik Hager, Laura Hoffmeister, Nina Kausch-Busies, David Wilcke, Matthieu Willot, Kerstin Ilg
  • Patent number: 11072601
    Abstract: Disclosed are a class of ?-opioid receptor agonists and a preparation method therefor and the use thereof in the field of medicine, belonging to the field of medicinal chemistry. The ?-opioid receptor agonists significantly increase the selectivity for a G protein signaling pathway, and not only can exhibit excellent pharmacodynamic effects, but also significantly improve safety.
    Type: Grant
    Filed: September 17, 2018
    Date of Patent: July 27, 2021
    Assignees: SHANGHAI SYNERGY PHARMACEUTICAL SCIENCES CO., LTD., ZHEJIANG HUAHAI PHARMACEUTICAL CO., LTD.
    Inventors: Xin Xu, Zhen Zhang, Yunfei Li, Liming Zhang, Fengying Guo, Qingyun Jiang, Dongsheng Li, Linli Zhang, Jinqian Song, Lei Liu, Qiang Liu, Jing Su, Yijin Wang, Jian Ge
  • Patent number: 11072611
    Abstract: The present invention discloses compounds according to Formula I: Wherein R1a, R1b, R2, R4, R5, R6a, R6b, R8, W, X, Cy, and the subscript a are as defined herein. The present invention relates to compounds inhibiting autotaxin (NPP2 or ENPP2), methods for their production, pharmaceutical compositions comprising the same, and methods of treatment using the same, for the prophylaxis and/or treatment of diseases involving fibrotic diseases, proliferative diseases, inflammatory diseases, autoimmune diseases, respiratory diseases, cardiovascular diseases, neurodegenerative diseases, dermatological disorders, and/or abnormal angiogenesis associated diseases by administering the compound of the invention.
    Type: Grant
    Filed: November 13, 2019
    Date of Patent: July 27, 2021
    Assignee: GALAPAGOS NV
    Inventors: Nicolas Desroy, Bertrand Heckmann, Reginald Christophe Xavier Brys, Agnès Marie Joncour, Christophe Peixoto, Xavier Marie Bock
  • Patent number: 11066420
    Abstract: Protein tyrosine phosphatases (PTPs) are key regulators of metabolism and insulin signaling. As a negative regulator of insulin signaling, the low molecular weight protein tyrosine phosphatase (LMPTP) is a target for insulin resistance and related conditions. Described herein are compounds capable of modulating the level of activity of low molecular weight protein tyrosine phosphatase (LMPTP) and compositions, and methods of using these compounds and compositions.
    Type: Grant
    Filed: April 27, 2018
    Date of Patent: July 20, 2021
    Assignee: SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE
    Inventors: Anthony B. Pinkerton, Robert J. Ardecky, Jiwen Zou
  • Patent number: 11053241
    Abstract: The present invention provides compounds, compositions thereof, and methods of using the same for the inhibition of TYK2, and the treatment of TYK2-mediated disorders.
    Type: Grant
    Filed: November 27, 2019
    Date of Patent: July 6, 2021
    Assignee: Nimbus Lakshmi, Inc.
    Inventors: Jeremy Robert Greenwood, Craig E. Masse
  • Patent number: 11053238
    Abstract: The present invention relates to benzimidazole compounds useful in treating for protein kinase-associated disorders. There is also a need for compounds useful in the treatment or prevention of one or more symptoms of cancer, transplant rejections. Furthermore, there is a need for methods for modulating the activity of protein kinases, such as CDK4 and/or CDK6, using the compounds provided herein.
    Type: Grant
    Filed: December 22, 2017
    Date of Patent: July 6, 2021
    Assignee: BETTA PHARMACEUTICALS CO., LTD.
    Inventors: Yiqian Wang, Jiabing Wang, Lieming Ding
  • Patent number: 11046686
    Abstract: A compound of Formula (I): pharmaceutically acceptable salts thereof, deuterated analogs thereof, compositions thereof, and methods of treating disease using a compound thereof are disclosed.
    Type: Grant
    Filed: August 13, 2019
    Date of Patent: June 29, 2021
    Assignee: Gilead Sciences, Inc.
    Inventors: Stephen Ammann, Elizabeth M. Bacon, Gediminas Brizgys, Elbert Chin, Chienhung Chou, Jeromy J. Cottell, Marilyn Ndukwe, Marina Shatskikh, James G. Taylor, Nathan E. Wright, Zheng-Yu Yang, Sheila M. Zipfel
  • Patent number: 11034648
    Abstract: The present invention relates to novel derivatives of cystobactamides of formula (Ib) and the use thereof for the treatment or prophylaxis of bacterial infections.
    Type: Grant
    Filed: August 23, 2018
    Date of Patent: June 15, 2021
    Assignees: HELMHOLTZ-ZENTRUM FÜR, INFEKTIONSFORSCHUNG GMBH
    Inventors: Giambattista Testolin, Mark Brönstrup, Hans-Peter Prochnow, Jennifer Herrmann, Rolf Müller, Charlotte Grandclaudon, Tim Mollner, Antje Ritter
  • Patent number: 11026924
    Abstract: The present invention provides 1H-pyrazolo[4,3-b]pyridin-7-amines of formula (1) as PDE1 inhibitors and their use as a medicament, in particular for the treatment of neurodegenerative disorders and psychiatric disorders.
    Type: Grant
    Filed: October 1, 2020
    Date of Patent: June 8, 2021
    Assignee: H. Lundbeck A/S
    Inventors: Jan Kehler, Karsten Juhl, Mauro Marigo, Paulo Jorge Vieira Vital, Mikkel Jessing, Morten Langgård, Lars Kyhn Rasmussen, Carl Martin Sebastian Clementson
  • Patent number: 11028085
    Abstract: The present invention provides compounds, compositions thereof, and methods of using the same for the inhibition of HPK1, and the treatment of HPK1-mediated disorders.
    Type: Grant
    Filed: September 14, 2020
    Date of Patent: June 8, 2021
    Assignee: Nimbus Saturn, Inc.
    Inventors: Neelu Kaila, Ian Linney, Stuart Ward, Grant Wishart, Ben Whittaker, Alexandre Cote, Jeremy Robert Greenwood, Abba Leffler, Steven K. Albanese, Daniel L. Severance
  • Patent number: 11026923
    Abstract: The present invention provides 1H-pyrazolo[4,3-b]pyridin-7-amines of formula (I) as PDE1 inhibitors and their use as a medicament, in particular for the treatment of neurodegenerative disorders and psychiatric disorders.
    Type: Grant
    Filed: October 1, 2020
    Date of Patent: June 8, 2021
    Assignee: H. Lundbeck A/S
    Inventors: Jan Kehler, Karsten Juhl, Mauro Marigo, Paulo Jorge Vieira Vital, Mikkel Jessing, Morten Langgård, Lars Kyhn Rasmussen, Carl Martin Sebastian Clementson
  • Patent number: 11028101
    Abstract: A compound of formula Ia, Ib, Ic or Id: wherein: n is 1 or 2; RN is H or Me; R1 is optionally one or more halo or methyl groups; R2a and R2b are independently selected from the group consisting of: (i) F; (ii) H; (iii) Me; and (iv) CH2OH; R2c and R2d (if present) are independently selected from the group consisting of: (i) F; (ii) H; (iii) Me; and (iv) CH2OH; R3a and R3b are independently selected from H and Me; R4a is selected from OH, —NH2, —C(?O)NH2, and —CH2OH; R4b is either H or Me; R5 is either H or Me; m is 1 or 2; q is 0 or 1; R11a, R11b, R11c and R11d are independently selected from H, halo, C1-4 alkyl, C1-4 fluoroalkyl, C3-4 cycloalkyl, C1-4 alkyloxy, NH—C1-4 alkyl and cyano; R12a and R12b are independently selected from the group consisting of: (i) F; (ii) H; (iii) Me; and (iv) CH2OH; R12c and R12d are independently selected from the group consisting of: (i) F; (ii) H; (iii) Me; and (iv) CH2OH; R12e is H or Me; R13a and R13b are independently selected from H and Me; R14 is either H or Me; R16a
    Type: Grant
    Filed: November 18, 2019
    Date of Patent: June 8, 2021
    Assignee: CTXT PTY LTD
    Inventor: Paul Anthony Stupple
  • Patent number: 11021481
    Abstract: The present invention provides compounds, compositions thereof, and methods of using the same for the inhibition of HPK1, and the treatment of HPK1-mediated disorders.
    Type: Grant
    Filed: September 14, 2020
    Date of Patent: June 1, 2021
    Assignee: Nimbus Saturn, Inc.
    Inventors: Neelu Kaila, Ian Linney, Stuart Ward, Grant Wishart, Ben Whittaker, Alexandre Cote, Jeremy Robert Greenwood, Abba Leffler, Steven K. Albanese, Daniel L. Severance
  • Patent number: 11021447
    Abstract: A compound, or a protonate or salt thereof, of formula I: wherein Y is aryl, substituted aryl, heteroaryl, or substituted heteroaryl; n is 1 or 2; each R10 is independently alkyl, substituted alkyl, a polyether moiety, carboxyl, substituted carboxyl, alkoxy, substituted alkoxy, haloalkyl, halogen, nitro, amino, aryloxy, aryl, substituted aryl, cyano, hydroxyl, carbonylamino, aminocarbonyl, acyl, sulfonyl, or substituted sulfonyl; a is 0 to 4; is an aryl or heteroaryl ring; and each R is independently halogen, carbonylamino, sulfonamide, carboxylic acid or hydrogen, provided at least one R is a halogen; and provided that if Y is are not respectively.
    Type: Grant
    Filed: May 1, 2019
    Date of Patent: June 1, 2021
    Assignees: University of Oregon, University of Montana
    Inventors: Jessica Lohrman, Darren W. Johnson, Michael M. Haley, Orion B. Berryman, Asia M. Riel, Daniel A. Decato
  • Patent number: 11021478
    Abstract: This invention relates to indolizine derivatives and their use in medicine. In particular, the present invention discloses novel substituted indolizine derivatives of formula I, or an isotopically labeled compound thereof, or an optical isomer thereof, a geometric isomer thereof, a tautomer thereof or a mixture of various isomers, or a pharmaceutically acceptable salt thereof, or a prodrug thereof. The invention also relates to the use of these compounds in medicine.
    Type: Grant
    Filed: May 8, 2018
    Date of Patent: June 1, 2021
    Assignee: KIND PHARMACEUTICAL
    Inventors: Dong Liu, Dongdong Chen, Biao Deng, Xiangyun Tu, Zinan Fang, Haohao Wu, Danyan Gu
  • Patent number: 11021479
    Abstract: The present invention relates to novel 11-oxo-11H-pyrido[2,1-b]quinazoline-6-carboxamide derivatives as potent inhibitors of protein kinase, to pharmaceutical compositions containing them and to the use of said compounds for the manufacture of a drug for the treatment of diseases or pathological diseases that can be improved by inhibiting protein kinase.
    Type: Grant
    Filed: May 31, 2018
    Date of Patent: June 1, 2021
    Assignee: ONCOSTELLAE, S.L.
    Inventors: Guido Kurz, Juan Camacho Gómez
  • Patent number: 11021490
    Abstract: The present invention relates to a pyridinium oxazole dyad scaffold of formula (I) and a process for the preparation thereof. The present invention further discloses a pyridine compound of formula (II) which is used for the preparation of formula (I) and a process for preparation thereof.
    Type: Grant
    Filed: February 26, 2020
    Date of Patent: June 1, 2021
    Assignee: Council of Scientific and Industrial Research
    Inventors: Nitin Tukaram Patil, Aslam Chandbhai Shaikh, Prasad Padmakar Kulkarni, Dnyanesh Sadanand Ranade
  • Patent number: 11014885
    Abstract: Disclosed is a new method for preparing a donepezil pamoate (1-benzyl-4-[(5,6-dimethoxyindan-2-one)methyl]piperidine pamoate). The donepezil pamoate prepared by using the method has a high purity and a good flowability.
    Type: Grant
    Filed: June 5, 2018
    Date of Patent: May 25, 2021
    Assignees: Zhejiang Huahai Pharmaceutical Co., Ltd., Shanghai Aobo Pharmtech, Inc., Ltd.
    Inventors: Wei Xu, Xi Chen, Hong Gu
  • Patent number: 11008297
    Abstract: The present invention relates to the unexpected discovery of novel multi-aromatic, multi-substituted compounds. In certain embodiments, the compounds of the invention are generated by condensing at least two phenolic- and/or aniline-containing monomers and an aromatic, aliphatic or heteroaromatic aldehyde- and/or ketone-containing monomer. In other embodiments, at least one monomer is isolated from a bio-based resource. In yet other embodiments, the compounds of the invention are bis- or poly-phenolic compounds.
    Type: Grant
    Filed: May 15, 2018
    Date of Patent: May 18, 2021
    Assignees: Rowan University, The United States of America as Represented by the Secretary of the Army
    Inventors: Alexander W. Bassett, Joseph F. Stanzione, III, John J. La Scala, Joshua M. Sadler, Owen M. Stecca
  • Patent number: 10981891
    Abstract: The present invention relates to compounds of formula (I) including any stereochemically isomeric form thereof, or pharmaceutically acceptable salts thereof, for the treatment of tuberculosis.
    Type: Grant
    Filed: October 14, 2019
    Date of Patent: April 20, 2021
    Assignees: The Global Alliance for TB Drug Development, Inc., Janssen Pharmaceutica NV
    Inventors: Anna Marie Upton, Christopher Blair Cooper, Koenraad Jozef Lodewijk Marcel Andries, Jerome Emile Georges Guillemont, Walter Marcel Mathilde Van den Broeck, Brian Desmond Palmer, Zhenkun Ma